A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...

For decades, Jeff Card's family company was known for manufacturing the once ubiquitous tin boxes where people could buy ...

Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

The poisonous flower yellow oleander is showing up in diet supplements. There are now warnings for 22 dietary supplements ...

Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors.

On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

The FDA claimed these clinics were plying patients with an illegal drug derived from their stem cells. A federal court agrees ...

Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.

The panel agreed with the FDA that the treatment in which a patient's tissue is processed doesn't fall under the same ...

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. In a new ...